| Literature DB >> 26690140 |
Qun Zhao1,2, Min Yang3, Yanping Deng4, Haitao Yu5, Linlin Wang6, Fukang Teng7,8, Kenka Cho9, Hongmei Ma10, Peng Wu11,12, Xue Li13, Wanying Wu14, Xuan Liu15, Feng Xu16, Baohong Jiang17, De-An Guo18.
Abstract
Our previous study indicated that the combination of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1), the main components of Salvia miltiorrhizae and Panax notoginseng, improves myocardium structure and ventricular function in rats with ischemia/reperfusion injury. The present study aimed to determine the safety of the combined SalB and Rg1 (SalB-Rg1) in mice. The safety of SalB-Rg1 was evaluated through acute toxicity and repeated-dose toxicity. In the acute toxicity study, the up and down procedure was carried out firstly, and then, the Bliss method was applied. In the toxicity study for seven-day repeated treatment of SalB-Rg1, forty Kunming mice were randomly divided into four groups. The intravenous median lethal dose (LD50) of the SalB-Rg1 combination was 1747 mg/kg using the Bliss method. For both the acute toxicity study and the seven-day repeated toxicity study, SalB-Rg1 did not induce significant abnormality on brain, heart, kidney, liver and lung structure at any dose based on H&E stain. There were no significant changes related to the SalB-Rg1 toxicity detected on biochemical parameters for two kinds of toxicity studies. The LD50 in mice was 1747 mg/kg, which was more than one hundred times higher than the effective dose. Both studies of acute toxicity and seven-day repeated dose toxicity indicated the safety of the SalB-Rg1 combination.Entities:
Keywords: acute toxicity; ginsenoside Rg1; repeated toxicity; safety; salvianolic acid B
Mesh:
Substances:
Year: 2015 PMID: 26690140 PMCID: PMC4691119 DOI: 10.3390/ijms161226176
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Representative chromatograms of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1). (A) The purity of SalB was 98.46%; and (B) the purity of Rg1 was 98.35%.
Figure 2The sequence of the up and down procedure. The surviving animals are marked as green circles and the dead animals as a red cross. The initial dose was 175 mg/kg of the SalB-Rg1 combination.
Figure 3The survival curve for acute toxicity. All of the deaths occurred within 24 h after intravenous administration of SalB-Rg1.
Effects of SalB-Rg1 on body weight and survival number with a single dose in acute toxicity.
| Day 0 | Day 7 | Day 14 | |||||
|---|---|---|---|---|---|---|---|
| Dose (mg/kg) | Body Weight (g) | Animal Number | Body Weight (g) | Animal Number | Body Weight (g) | Animal Number | |
|
| 0 | 38.1 ± 2.1 | 5 | 42.2 ± 3.3 | 5 | 40.6 ± 3.2 | 5 |
| 1381 | 37.5 ± 1.9 | 5 | 40.6 ± 1.8 | 5 | 40.4 ± 1.9 | 5 | |
| 1535 | 38.5 ± 2.5 | 5 | 42.2 ± 3.0 | 5 | 42.0 ± 2.9 | 5 | |
| 1706 | 38.0 ± 2.5 | 3 | 40.0 ± 3.3 | 3 | 39.5 ± 2.9 | 3 | |
| 1895 | 37.6 ± 1.2 | 1 | 38.7 | 1 | 35.7 | 1 | |
| 2106 | 38.3 ± 2.1 | 0 | – | – | – | – | |
|
| 0 | 32.1 ± 1.2 | 5 | 33.8 ± 1.7 | 5 | 35.6 ± 1.7 | 5 |
| 1381 | 30.5 ± 1.3 | 5 | 31.5 ± 1.9 | 5 | 33.8 ± 2.1 | 5 | |
| 1535 | 31.7 ± 2.0 | 4 | 33.7 ± 1.9 | 3 | 33.4 ± 1.7 | 3 | |
| 1706 | 30.5 ± 1.6 | 2 | 35.2 ± 0.1 | 2 | 32.4 ± 0.2 | 2 | |
| 1895 | 29.9 ± 2.4 | 2 | 31.5 ± 2.5 | 2 | 32.1 ± 2.1 | 2 | |
| 2106 | 30.3 ± 1.6 | 1 | 30.9 | 1 | 31.3 | 1 | |
Values are expressed as the mean ± SD.
Effects of SalB-Rg1 with a single dose on the organ index in acute toxicity.
| Organ Index (g/kg) | Dose Group (mg/kg) | |||||
|---|---|---|---|---|---|---|
| 0 | 1381 | 1535 | 1706 | 1895 | 2106 | |
|
| ||||||
| Brain | 8.4 ± 1.5 | 9.2 ± 0.8 | 8.9 ± 0.8 | 8.5 ± 0.3 | 10.6 | – |
| Heart | 5.1 ± 0.2 | 5.4 ± 0.6 | 5.6 ± 0.7 | 4.7 ± 0.7 | 4.5 | – |
| Kidney | 15.4 ± 1.3 | 15.2 ± 1.3 | 15.2 ± 0.8 | 16.7 ± 2.2 | 17.9 | – |
| Liver | 39.9 ± 3.7 | 45.1 ± 5.4 | 43.8 ± 1.9 | 40.1 ± 0.8 | 44.7 | – |
| Lung | 7.1 ± 0.9 | 7.1 ± 1.0 | 6.8 ± 1.5 | 6.6 ± 0.7 | 7.27 | – |
| Spleen | 2.4 ± 0.4 | 3.7 ± 1.9 | 2.5 ± 0.6 | 3.4 ± 1.5 | 4.5 | – |
|
| ||||||
| Brain | 9.9 ± 1.0 | 10.8 ± 1.4 | 11.7 ± 2.6 | 13.3 ± 1.1 | 11.1 ± 2.0 | 11 |
| Heart | 4.8 ± 0.4 | 5.7 ± 0.4 | 5.8 ± 0.5 | 5.2 ± 0.4 | 3.5 ± 0.4 | 6.6 |
| Kidney | 12.6 ± 1.5 | 13.0 ± 1.4 | 13.5 ± 2.0 | 13.3 ± 0.4 | 13.2 ± 0.2 | 13.4 |
| Liver | 43.7 ± 4.7 | 46.0 ± 3.9 | 45.0 ± 3.0 | 38.5 ± 0.17 | 50.8 ± 0.8 | 43.5 |
| Lung | 7.22 ± 1.3 | 6.9 ± 0.7 | 6.9 ± 1.2 | 6.9 ± 0.2 | 7.02 ± 0.5 | 6.4 |
| Spleen | 3.5 ± 0.3 | 4.1 ± 0.5 | 4.8 ± 0.6 ** | 2.6 ± 0.38 | 5.8 ± 0.4 ** | 3.7 |
Values are expressed as the mean ± SD. ** p < 0.01 compared to the control group.
Figure 4Representative histological pictures of heart (A), kidney (B), spleen (C), brain (D), lung (E) and liver (F) staining with H&E in the acute toxicity study (magnification 400×).
Effects of SalB-Rg1 with a single dose on the biochemical parameters in acute toxicity.
| Dose Group (mg/kg) | ||||||
|---|---|---|---|---|---|---|
| 0 | 1381 | 1535 | 1706 | 1895 | 2106 | |
|
| ||||||
| Cr (μmol/L) | 201.2 ± 88.2 | 159.5 ± 38.8 | 193.6 ± 12.4 | 162.3 ± 87.2 | – | – |
| TP (mg/mL) | 48.7 ± 2.4 | 41.2 ± 7.0 | 38.5 ± 7.5 | 45.2 ± 10.8 | – | – |
| Alb (mg/mL) | 19.2 ± 2.2 | 19.7 ± 4.6 | 17.3 ± 3.7 | 18.6 ± 3.3 | – | – |
|
| ||||||
| Cr (μmol/L) | 125.3 ± 81.3 | 153.8 ± 58.7 | 100.6 ± 71.7 | 323.3 ± 194.6 | 162.3 ± 33.6 | 176.5 |
| TP (mg/mL) | 44.0 ± 3.7 | 41.0 ± 2.2 | 47.5 ± 6.5 | 47.9 ± 3.0 | 41.7 ± 6.2 | 23.2 |
| Alb (mg/mL) | 20.2 ± 2.9 | 18.0 ± 3.8 | 16.8 ± 1.0 | 19.7 ± 0.2 | 17.9 ± 3.2 | 47.8 |
Values are expressed as the mean ± SD. Cr: creatinine; TP; total protein; Alb: albumin.
Effects of SalB-Rg1 on body weight and survival number with seven-day repeated dose toxicity.
| Day 0 | Day 7 | Day 14 | |||||
|---|---|---|---|---|---|---|---|
| Dose (mg/kg) | Body Weight (g) | Animal Number | Body Weight (g) | Animal Number | Body Weight (g) | Animal Number | |
|
| 0 | 23.5 ± 1.1 | 5 | 27.4 ± 1.5 | 5 | 30.8 ± 2.2 | 5 |
| 15 | 23.5 ± 1.1 | 5 | 27.4 ± 1.5 | 5 | 30.8 ± 2.2 | 5 | |
| 30 | 22.8 ± 0.8 | 5 | 26.4 ± 1.1 | 5 | 30.0 ± 1.5 | 5 | |
| 60 | 23.1 ± 0.9 | 5 | 27.0 ± 1.3 | 5 | 30.0 ± 1.3 | 5 | |
|
| 0 | 22.2 ± 1.2 | 5 | 24.7 ± 1.3 | 5 | 26.6 ± 1.1 | 5 |
| 15 | 22.9 ± 0.7 | 5 | 26.9 ± 1.0 | 5 | 26.8 ± 1.2 | 5 | |
| 30 | 23.0 ± 0.7 | 5 | 26.6 ± 2.2 | 5 | 28.5 ± 1.2 | 5 | |
| 60 | 22.2 ± 1.5 | 5 | 25.7 ± 1.9 | 5 | 26.7 ± 1.7 | 5 | |
Values are expressed as the mean ± SD.
Effects of SalB-Rg1 on the organ index with a seven-day repeated dose.
| Organ Index (g/kg) | Dose Group (mg/kg) | |||
|---|---|---|---|---|
| 0 | 15 | 30 | 60 | |
|
| ||||
| Brain | 11.5 ± 1.2 | 11.6 ± 1.1 | 11.8 ± 1.3 | 11.7 ± 1.1 |
| Heart | 5.7 ± 0.5 | 5.2 ± 0.3 | 5.8 ± 0.5 | 5.5 ± 0.5 |
| Kidney | 14.0 ± 0.7 | 13.6 ± 0.6 | 13.0 ± 1.3 | 13.6 ± 0.9 |
| Lung | 7.3 ± 0.4 | 6.6 ± 0.4 | 7.0 ± 0.5 | 6.8 ± 0.6 |
| Spleen | 8.3 ± 3.4 | 6.4 ± 0.4 | 6.8 ± 0.7 | 6.1 ± 0.4 |
|
| ||||
| Brain | 13.4 ± 1.7 | 12.6 ± 1.0 | 12.1 ± 1.3 | 13.6 ± 0.5 |
| Heart | 5.1 ± 0.5 | 4.9 ± 0.2 | 4.9 ± 0.5 | 4.8 ± 0.5 |
| Kidney | 13.3 ± 0.6 | 13.5 ± 1.1 | 13.4 ± 0.9 | 12.4 ± 0.9 |
| Lung | 8.2 ± 1.8 | 7.5 ± 0.7 | 6.8 ± 1.1 | 7.4 ± 1.2 |
| Spleen | 7.3 ± 0.9 | 6.5 ± 1.0 | 5.9 ± 1.2 | 6.3 ± 1.2 |
Values are expressed as the mean ± SD.
Figure 5Representative histological pictures of heart (A), kidney (B), spleen (C), brain (D), lung (E) and liver (F) staining with H&E in the seven-day repeated toxicity study (magnification 400×).
Effects of SalB-Rg1 on biochemical parameters with a seven-day repeat dose.
| Dose Group (mg/kg) | ||||
|---|---|---|---|---|
| 0 | 15 | 30 | 60 | |
|
| ||||
| Cr (μmol/L) | 76.3 ± 49.8 | 38.7 ± 22.0 | 67.1 ± 11.3 | 58.9 ± 12.3 |
| TP (mg/mL) | 52.3 ± 5.4 | 56.1 ± 5.4 | 52.4 ± 4.9 | 52.7 ± 5.6 |
| Alb (mg/mL) | 28.0 ± 3.2 | 29.6 ± 1.7 | 28.5 ± 4.9 | 28.6 ± 3.1 |
|
| ||||
| Cr (μmol/L) | 81.5 ± 14.7 | 81.5 ± 10.6 | 70.2 ± 17.4 | 44.5 ± 20.6 * |
| TP (mg/mL) | 54.3 ± 3.9 | 56.4 ± 4.9 | 54.1 ± 6.9 | 53.1 ± 4.6 |
| Alb (mg/mL) | 28.7 ± 3.3 | 28.7 ± 1.8 | 29.2 ± 3.5 | 33.3 ± 3.9 |
Values are the mean ± SD. Cr: creatinine, TP: total protein, Alb: albumin. Compared to the control group: * p < 0.05.